MSD: Molnupiravir el más avanzado de los antivirales para Covid19

 

De los antivirales en desarrollo para la covid-19, molnupiravir, el candidato de MSD y Ridgeback Biotherapeutics, es con mucho el más avanzado en el desarrollo clínico, según publica la web especializada Evaluate Vantage, dependiente de la consultora Evaluate. El pasado sábado las compañías presentaron resultados positivos en pacientes no hospitalizados de un ensayo en fase IIa auspiciado por Ridgeback con este antiviral, inicialmente concebido como antigripal, durante la Conferencia sobre Retrovirus e Infecciones Oportunistas (CROI 2021) que se celebra anualmente.

  Diario Médico

 

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)-- 

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. 

At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo-treated patients (53/377); p=0.0012. Through Day 29, no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo. At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration (FDA), recruitment into the study is being stopped early due to these positive results. Merck plans to submit an application for Emergency Use Authorization (EUA) to the U.S. FDA as soon as possible based on these findings and plans to submit marketing applications to other regulatory bodies worldwide.

“More tools and treatments are urgently needed to fight the COVID-19 pandemic, which has become a leading cause of death and continues to profoundly affect patients, families, and societies and strain health care systems all around the world. With these compelling results, we are optimistic that molnupiravir can become an important medicine as part of the global effort to fight the pandemic and will add to Merck’s unique legacy of bringing forward breakthroughs in infectious diseases when they are needed most. Consistent with Merck’s unwavering commitment to save and improve lives, we will continue to work with regulatory agencies on our applications and do everything we can to bring molnupiravir to patients as quickly as possible,” said Robert M. Davis, chief executive officer and president, Merck.

 Más